Emerald Health Therapeutic (TSXV: EMH) (OTCQX: EMHTF), a licensed Canadian medical marijuana producer, has impressively raised $18M from a single accredited investor. Emerald has issued 3,000,000 units at a price of $6.00 per, with each unit consisting of one common share and one warrant.
Emerald plans to use the capital on the expansion of their R&D program as well as general operations for its subsidiary, which is dedicated to researching, developing, and distributing medical grade cannabis products for their patients in Canada. Emerald Health Botanicals sells a variety of THC and CBD products including tinctures and dry herbs on the company’s website and is federally licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR) in Canada.
About the CEO of Inc. CEO, Chris Wagner, has more than 25 years marketing pharmaceutical products and building biotech companies. Mr. Wagner most recently served as Chairman, President, and CEO of Contextual Genomics In, a molecular bioinformatics company that has worked to develop genomic cancer diagnostic products.